{"id":2632,"date":"2015-11-04T20:15:00","date_gmt":"2015-11-04T20:15:00","guid":{"rendered":"https:\/\/cdafound.org\/?p=2632"},"modified":"2025-01-15T20:35:40","modified_gmt":"2025-01-15T20:35:40","slug":"the-estimated-future-disease-burden-of-hepatitis-c-virus-in-the-netherlands-with-different-treatment-paradigms","status":"publish","type":"post","link":"https:\/\/cdafound.org\/es\/the-estimated-future-disease-burden-of-hepatitis-c-virus-in-the-netherlands-with-different-treatment-paradigms\/","title":{"rendered":"La carga estimada de morbilidad futura del virus de la hepatitis C en los Pa\u00edses Bajos con diferentes paradigmas de tratamiento"},"content":{"rendered":"<h2 class=\"wp-block-heading\">Resumen<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\">Antecedentes y objetivos<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">La prevalencia de la infecci\u00f3n por el virus de la hepatitis C (VHC) en los Pa\u00edses Bajos es baja (prevalencia anti-VHC 0,22%). El tratamiento totalmente oral con antivirales de acci\u00f3n directa (AAD) es tolerable y eficaz, pero caro. Nuestro an\u00e1lisis proyect\u00f3 la futura carga de morbilidad relacionada con el VHC en los Pa\u00edses Bajos mediante la aplicaci\u00f3n de diferentes escenarios de tratamiento. <\/p>\n\n\n\n<h3 class=\"wp-block-heading\">M\u00e9todos<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Utilizando un enfoque de modelizaci\u00f3n, se estim\u00f3 el tama\u00f1o de la poblaci\u00f3n vir\u00e9mica del VHC en los Pa\u00edses Bajos en 2014 utilizando los datos disponibles y el consenso de expertos. Se model\u00f3 el escenario base (basado en la situaci\u00f3n holandesa actual) y diferentes escenarios de tratamiento (con mayor eficacia, aceptaci\u00f3n del tratamiento y diagn\u00f3sticos) y se predijo la carga futura de enfermedad por VHC para cada escenario. <\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Resultados<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">El n\u00famero estimado de personas con infecci\u00f3n vir\u00e9mica por VHC en los Pa\u00edses Bajos en 2014 fue de 19.200 (prevalencia 0,12%). Para 2030, se prev\u00e9 que este n\u00famero disminuya en 45% en el escenario base y en 85% si aumenta el n\u00famero de pacientes tratados. Adem\u00e1s, se estima que el n\u00famero de personas con carcinoma hepatocelular y muertes relacionadas con el h\u00edgado disminuir\u00e1 en 19% y 27%, respectivamente, en el escenario base, pero ambos pueden disminuir a\u00fan m\u00e1s en 68% cuando se enfoca en el tratamiento de pacientes con VHC en una etapa de fibrosis de = F2.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Pa\u00edses:<\/strong> Los pa\u00edses bajos<\/p>\n\n<div class=\"wp-block-buttons is-content-justification-center is-layout-flex wp-block-buttons-is-layout-flex\">\n<div class=\"wp-block-button is-style-outline is-style-outline--1\"><a class=\"wp-block-button__link has-text-color wp-element-button\" href=\"https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26582807\" target=\"_blank\" rel=\"noreferrer noopener\">Lea el informe completo<\/a><\/div>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>Summary Background &amp; Aims Prevalence of hepatitis C virus (HCV) infection in the Netherlands is low (anti-HCV prevalence 0.22%). All-oral treatment with direct-acting antivirals (DAAs) is tolerable and effective but expensive. Our analysis projected the future HCV-related disease burden in the Netherlands by applying different treatment scenarios. Methods Using a modelling approach, the size of [&hellip;]<\/p>\n","protected":false},"author":24,"featured_media":3496,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[9],"tags":[10],"publication-author":[1249,1243,1244,1088,494,497,1250,1245,1248,1251,1247,1242,1246],"class_list":["post-2632","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-publication","tag-hcv","publication-author-croes-ea","publication-author-de-knegt-rj","publication-author-de-vree-jm","publication-author-prins-m","publication-author-razavi-h","publication-author-razavi-shearer-d","publication-author-reesink-hw","publication-author-van-der-meer-aj","publication-author-van-santen-dk","publication-author-veldhuijzen-ik","publication-author-willemse-sb","publication-author-zaaijer-hl","publication-author-zuure-fr"],"acf":[],"_links":{"self":[{"href":"https:\/\/cdafound.org\/es\/wp-json\/wp\/v2\/posts\/2632","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cdafound.org\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cdafound.org\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cdafound.org\/es\/wp-json\/wp\/v2\/users\/24"}],"replies":[{"embeddable":true,"href":"https:\/\/cdafound.org\/es\/wp-json\/wp\/v2\/comments?post=2632"}],"version-history":[{"count":6,"href":"https:\/\/cdafound.org\/es\/wp-json\/wp\/v2\/posts\/2632\/revisions"}],"predecessor-version":[{"id":7592,"href":"https:\/\/cdafound.org\/es\/wp-json\/wp\/v2\/posts\/2632\/revisions\/7592"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cdafound.org\/es\/wp-json\/wp\/v2\/media\/3496"}],"wp:attachment":[{"href":"https:\/\/cdafound.org\/es\/wp-json\/wp\/v2\/media?parent=2632"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cdafound.org\/es\/wp-json\/wp\/v2\/categories?post=2632"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cdafound.org\/es\/wp-json\/wp\/v2\/tags?post=2632"},{"taxonomy":"publication-author","embeddable":true,"href":"https:\/\/cdafound.org\/es\/wp-json\/wp\/v2\/publication-author?post=2632"}],"curies":[{"name":"gracias","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}